Protara Therapeutics, Inc.
TARA
$3.97
$0.030.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.98% | 1.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.82% | 2.88% | |||
| Operating Income | -18.82% | -2.88% | |||
| Income Before Tax | -21.85% | -2.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.85% | -2.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.85% | -2.74% | |||
| EBIT | -18.82% | -2.88% | |||
| EBITDA | -19.00% | -2.91% | |||
| EPS Basic | -14.95% | 17.80% | |||
| Normalized Basic EPS | -14.91% | 17.75% | |||
| EPS Diluted | -14.95% | 17.80% | |||
| Normalized Diluted EPS | -14.91% | 17.75% | |||
| Average Basic Shares Outstanding | 6.03% | 24.97% | |||
| Average Diluted Shares Outstanding | 6.03% | 24.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||